Alendronate treatment in patients with osteoarthritis of the hip associated with osteoporosis

Phase 4

• Conditions: Osteoarthritis of the hip

• Registration Number: JPRN-UMIN000001150
• Lead Sponsor: Osaka Osteo-Arthritis Forum (OAF)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-01
• Study Completion: 2012-10-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 210

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patient who has willing to receive surgery of the hip, or who is scheduled to receive surgery of the hip, at the entry of the study 2) Patient who has willing to bear a child or who is a nursing mother 3) Patient who has serious renal disorder 4) Patient who has experiences of receiving bisphosphonate treatment within 6 months at inclusion of the study 5) Patient who has experiences of receiving drugs having influence on bone remodeling rwithin 8 weeks at inclusion of the study (Vitamin D, Calcitonin, Ipriflavone, Vitamin K, Steroid) 6) Patients with primary or secondary hyperparathyroidism, or with rheumatic arthritis 7) Patients with upper gastrointestinal disorders 8) Patients who is diagnosed as contraindication of alendronate treatements

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1) Plain anteroposterior radiographs of the hip (minimal joint space, position of the center of the femoral head, osteophyte, sclerotic chnage, porotic change) 2) WOMAC hip score, VAS score of the hip and knee Evaluation will be performed at the entry of the study, 3,6,12,18,24 months after start of the study

Secondary Outcome Measures

Name	Time	Method
1) Biochemical markers (Urinary NTX-I and CTX-II) 2) DEXA (Lumbar and hip) 3) MRI of the hip 4) Status of administration in alenronate and anti-inflamatory drugs